

**Company** Akers Biosciences, Inc.  
**TIDM** AKR  
**Headline** Director/PDMR Shareholding

Embargoed: 0700hrs, 9 April 2008

**Akers Biosciences, Inc.**  
(the "Company")

Director/PDMR Share Purchase

Akers Biosciences, Inc. a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the following acquisitions of shares in the Company by directors and persons disseminating managerial responsibility:

Thomas A. Nicolette, the Company's President and Chief Executive Officer, has exercised warrants over 1,737,619 common shares at par value increasing his shareholding in the Company to 2,393,636 common shares, representing approximately 3.38% of the enlarged issued share capital. These warrants are the primary instrument in Thomas A. Nicolette's remuneration package which began last year.

Edward Mulhare, Non Executive Director, has acquired 455,950 common shares at 13.75p per share through the Company's Direct Purchase Plan established at the 2007 Annual General Meeting of the Company. This investment by Edward Mulhare increases his holding in the Company to 1,356,890 common shares, representing approximately 1.92% of the enlarged issued share capital.

Robert J. Paratore, who was recently promoted to the position of Chief Financial Officer has exercised, for tax purposes only, options over 50,000 common shares at 10p per share. As a result of this exercise of options Robert J. Paratore now owns 60,000 shares in the Company, representing approximately 0.08% of the enlarged issued share capital.

Application has been made for the 2,243,569 common shares to be admitted to trading on AIM, such admission expected to take place on 14 April 2008.

Following Admission, the Company's enlarged issued share capital will comprise 70,797,789 common shares with voting rights. The Company does not hold any shares in treasury. This figure of 70,797,789 common shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

The exchange rate used for these transactions was 1.99384 USD to 1.00 GBP

**Enquiries:**

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons or Eleanor Williamson  
M:Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbuthnot Securities Limited  
Tel. +44 (0)20 7012 2000

END